Volume 32, Issue 213 (10-2022)                   J Mazandaran Univ Med Sci 2022, 32(213): 55-64 | Back to browse issues page

XML Persian Abstract Print

Abstract:   (795 Views)
Background and purpose: Hypoxemia and hypotension are important complications of hemodialysis in patients with chronic renal failure that are linked to several factors, including the type of filters used. The aim of this study was to compare the effect of simple filtration hemodialysis and ultrafiltration hemodialysis on blood pressure and blood arterial oxygen level.
Materials and methods: In this clinical trial, we studied 68 patients who underwent dialysis in Semnan Kosar Hospital in November and December 2019. Clinical information, including heart rate, blood pressure, and arterial oxygen saturation, and pulse oximeter reading for oxygen saturation level were recorded before and after every dialysis. The patients were randomly divided into two groups. One group received simple filtration hemodialysis in first month followed by ultrafiltration dialysis in next month, while other patients had ultrafiltration dialysis in first month followed by simple filtration hemodialysis in next month. Data analysis was carried out in SPSS V23.
Results: In ultrafiltration hemodialysis, arterial oxygen saturation at sessions two (P=0.037), five (P=0.002), and 11 (P>0.001) were found with significantly smaller changes compared with the first session. Also, in this type of filtration, changes in systolic blood pressure at sessions 12 (P=0.003) and 13 (P=0.034) were significantly smaller than the first session compared with the simple filtration dialysis.
Conclusion: Compared with simple filtration hemodialysis, ultrafiltration hemodialysis provides more oxygen stability and less hypotension and can minimize the side effects of dialysis.
Full-Text [PDF 348 kb]   (420 Downloads)    
Type of Study: Research(Original) | Subject: Nephrology

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.